Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Exact Sciences, Pfizer to Comarket Cologuard

Exact Sciences, Pfizer to Comarket Cologuard

Aug 22, 2018
|
staff reporter

NEW YORK (GenomeWeb) – Exact Sciences and Pfizer announced today that they have entered into an agreement to copromote Exact's colorectal cancer screening test Cologuard.

Investors welcomed the news by sending Exact's shares up more than 22 percent to $61.20 in morning trading on the Nasdaq.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Finds a Whole Bunch

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Away From the Field

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

PNAS Studies Look at Bacterial Detection Probes, Cholera Culprit Evolution in Environment, More

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

In a Different Lab

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

What's Popular?

In Business News

  1. Cue Health Awarded $13M BARDA Contract for POC Coronavirus Test

  2. Thermo Fisher Scientific Prices €1.2B Senior Notes Offering

  3. Luminex Receives Second BARDA Contract for $642K to Develop Rapid SARS-CoV-2 Test

  4. Color Gears Up to Enter COVID-19 Testing Space

  5. Rendu Biotechnology Gets Emergency Approval in China for Coronavirus Detection Kit

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.